Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease

Venus Remedies receives Ukrainian GMP approval for Its Carbapenem, Oncology parenteral facilities

The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations

Brinton appoints Amit Jain as President & Head of Domestic Business

Jain will have oversight of Brinton's domestic operations, including business development, sales, and marketing

Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development

Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing

PI Industries announces twin acquisitions into Pharma API & CDMO space

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.

Venus Remedies secures marketing authorization from UK MHRA for Cisplatin

Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country

Siegfried breaks ground on new R&D center for drug substances in Switzerland

The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth

Ashland diagnostic films medical device facilities achieve ISO certification

Gafchromic films support patient care in oncology

FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients